CTRI/2024/06/069335尚未招募Unknown
Scientific evaluation of the safety and efficacy of herbal and non-herbal formulations in mitigating hair fall, promoting hair growth, and preventing premature hair graying. - Nil
ovoBliss Research Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Age: 18 to 55 years and above (both inclusive) at the time of consent.
- •2)Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- •3)Females of childbearing potential must have a self-reported negative urine pregnancy.
- •4)Subject is in good general health as determined by the Investigator on the basis of medical history.
- •5)Female with 40-50 counts and male with 25 -30 counts of hair fall at screening.
- •6)Subject having AGA and premature Gray hair at a time of screening.
- •7)Subject having premature gray hair at a time of screening.
- •8)Subject with pro-claimed nonpathological thinning of hair.
- •9)Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
- •10)If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- •11)Subjects are willing to give written informed consent and are willing to follow the study procedure.
- •12)Subjects who commit not to use any other medicated/ prescription shampoos/hair care products (containing Minoxidil), any other hair growth products or hair colour or dye, other than the test products for the entire duration of the study.
- •13)Willing to use test products throughout the study period.
- •14)Subject is willing and able to follow and allow study staff to performed study test methods.
- •15)Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
- •16)Subject must be able to understand and provide written informed consent to participate in the study.
排除标准
- •1)Subject have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems.
- •2)Subject have history of any dermatological condition of the scalp other than hair loss and dandruff.
- •3)Subject have history of any prior hair growth procedures (e.g. hair transplant or laser).
- •4)Subject who had taken topical treatment of hair loss for at least 4 weeks.
- •5)Subject who had taken any systemic treatment for at least 3 months.
- •6)History of alcohol or drug addiction.
- •7)Subject having history or resent condition of irritated or visibly inflamed scalp or severe scalp disease.
- •8)Subject having history or present condition of an allergic response to any cosmetic products, any other condition which could warrant exclusion from the study.
- •9)Pregnant or breast feeding or planning to become pregnant during the study period.
- •10)History of chronic illness which may influence the cutaneous state.
- •11)Subject have participated any clinical research study related to hair care products.
- •12)Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
研究者
相似试验
已完成
不适用
The evaluation of the clinical effect and safety of stereotactic body radiationtherapy for hepatocellularcarcinomaJPRN-UMIN000016834Hiroshima university100
已完成
3 期
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2013012612274N1Vice-Chancellor for Research, Shahid Beheshti University of Medical Sciences100
已完成
3 期
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2014072118548N1Research Deputy of Kermanshah University Of Medical Sciences60
进行中（未招募）
1 期
Evaluation of the safety and efficacy of the treatment of chronic wounds in diabetic foot syndrome with the use of autologous stem cells isolated from adipose tissue - within the project: Therapeutic potential of adipose-derived stem cells, proven in clinical trials and examined in vitro - rationale for banking of well characterized cells”MedDRA version: 20.0 Level: LLT Classification code 10012664 Term: Diabetic foot ulcer System Organ Class: 100000004858Diabetic foot ulcerEUCTR2016-004109-15-PLMedical University of Warsaw50
已完成
不适用
Evaluation of the efficacy and the safety of processed onion product on human muscle metabolism for the inpatient.InpatientJPRN-UMIN000006087The University of Tokushima20